Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04690348 | Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study | PHASE2 | RECRUITING | 103 | — | — | Dec 24, 2020 | Dec 1, 2026 | Jan 13, 2026 | 6 | United States |
With a contrast enhanced brain MRI scan. Treatment response will be determined based on the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.
| Arm | Type | Description |
|---|---|---|
| Resection without brachytherapy | ACTIVE_COMPARATOR | Patients will undergo craniotomy. |
| Resection plus brachytherapy | EXPERIMENTAL | Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist. |
| Name | Type | Description |
|---|---|---|
| Craniotomy | PROCEDURE | Craniotomy |
| Cesium-131 brachytherapy | RADIATION | Intracavitary Cesium-131 brachytherapy |
Inclusion Criteria: * Adult patients ≥ 18 years of age who are capable of giving consent * Undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease at the time of consent, and anticipated achievement of gross-total or near-total (\>/...